Authored by Dr. Barrett
Part of the Hashimoto’s Research Review Series
In this series, I review newly published research on Hashimoto’s thyroiditis and explain what the findings mean for patients, separating promising science from conclusions that are not yet supported by the evidence.
State of the Evidence: Emerging with Strong Mechanistic Support
Growing body of evidence with plausible biological mechanisms. Clinically applicable with appropriate individualization.
One of the most frustrating experiences for people with Hashimoto’s is hearing that their thyroid numbers look “normal” while they still struggle with fatigue, brain fog, digestive symptoms, joint pain, or feeling unlike themselves.
For years, these lingering symptoms were often dismissed as unrelated to the thyroid. But a growing body of research suggests another system may deserve attention: gut health, particularly the trillions of microorganisms that make up the gut microbiome
Over the last five years, gut health has become one of the fastest-growing areas of Hashimoto’s research. What began as observational studies showing differences in the gut microbiome of people with Hashimoto’s has evolved into something much more compelling: evidence suggesting immune and metabolic pathways linking the gut microbiome to autoimmune thyroid disease.
While many questions remain unanswered, current evidence suggests the gut is not simply adjacent to thyroid health. It appears to participate in immune regulation, intestinal barrier integrity, thyroid hormone metabolism, and systemic inflammation.
Do People with Hashimoto’s Really Have Different Gut Bacteria?
Multiple systematic reviews and meta analyses now show that people with Hashimoto’s have measurable alterations in gut microbiome composition compared to healthy controls. However, the specific patterns identified are not entirely consistent across studies.
Findings related to microbial diversity have been mixed. Some studies report reduced bacterial richness and diversity, particularly in patients with overt hypothyroidism, while others have observed preserved or even increased diversity indices in Hashimoto’s populations. These inconsistencies likely reflect differences in geography, diet, sequencing methods, medication use, and disease stage.
Similarly, alterations involving Bifidobacterium, Lactobacillus, Bacteroides, Blautia, and Faecalibacterium have been repeatedly reported, but the direction of these shifts is not always uniform between studies.
Importantly, emerging research suggests the role of these organisms may depend less on whether they are universally “good” or “bad” bacteria and more on ecological balance, metabolic function, immune signaling, and strain specific behavior.
The gut microbiome also appears to influence several thyroid related processes simultaneously, including:
- Immune regulation
- Nutrient absorption
- Intestinal barrier integrity
- Thyroid hormone metabolism
This does not mean the microbiome is the sole driver of Hashimoto’s. Genetics, infections, stress physiology, micronutrient status, environmental exposures, sex hormones, and iodine intake all likely contribute. But the microbiome increasingly appears to be one meaningful piece of the puzzle.
Intestinal Permeability and Immune Regulation
One of the leading theories connecting the gut and thyroid involves increased intestinal permeability, often referred to as “leaky gut.”
The intestinal lining normally acts as a selective barrier, allowing nutrients into circulation while preventing bacterial toxins and inflammatory compounds from crossing into the bloodstream. Tight junction proteins help regulate this barrier.
Several studies in Hashimoto’s patients have demonstrated evidence of altered intestinal barrier function, including elevated circulating zonulin concentrations, although the clinical usefulness of commercially available zonulin testing remains controversial.
While the relationship between intestinal permeability and systemic immune activation remains incompletely understood, emerging evidence suggests barrier dysfunction may contribute to immune dysregulation in at least some patients with autoimmune thyroid disease.
Why Fiber May Matter More Than We Thought
One of the most important discoveries in this field involves short chain fatty acids (SCFAs), particularly butyrate.
SCFAs are produced when gut bacteria ferment dietary fiber. They play critical roles in:
- Supporting intestinal barrier integrity
- Reducing inflammatory signaling
- Promoting regulatory T cell activity
- Modulating immune function
In Hashimoto’s patients, several butyrate producing organisms, including Faecalibacterium prausnitzii, are altered in ways that may reduce SCFA production and impair gut barrier support.
This matters because butyrate is the preferred energy source for colonocytes and plays an important role in maintaining intestinal barrier integrity. Reduced SCFA production may therefore contribute to both increased permeability and dysregulated immune activity.
Several bacterial genera associated with SCFA production, including Akkermansia and members of the Ruminococcaceae family, have been associated with potentially protective metabolic and immunologic effects in some studies, although findings remain context dependent and are not entirely consistent across disease states or populations.
Clinically, this helps explain why dietary fiber diversity and prebiotic intake may matter far more than previously appreciated in Hashimoto’s care.
Is the Gut Causing Hashimoto’s, or Is It the Other Way Around?
One of the most important developments in recent years has been the emergence of Mendelian randomization studies examining the microbiome and autoimmune thyroid disease.
These studies use naturally occurring genetic differences that influence the microbiome, helping researchers evaluate potential causal relationships while reducing some of the confounding seen in observational research.
Several studies published between 2023 and 2025 identified specific bacterial taxa associated with either increased or decreased risk of Hashimoto’s thyroiditis. Some analyses also found that immune cell pathways partially mediated these effects, particularly involving dendritic cell signaling and inflammatory immune regulation.
Importantly, some studies found that microbiome patterns associated with Hashimoto’s risk were not simply a consequence of disease onset, supporting the possibility that dysbiosis may precede autoimmune activity in at least some individuals.
These findings do not establish definitive causality, and several reported associations did not remain significant after correction for multiple comparisons. However, they do provide preliminary evidence supporting potentially causal immune and metabolic pathways linking the microbiome and autoimmune thyroid disease.
Do Probiotics Help Hashimoto’s
The intervention literature is still early, but several findings are emerging consistently.
Intervention studies examining probiotics and synbiotics in autoimmune thyroid disease have produced mixed results.
Some individual trials have reported improvements in quality of life, inflammatory markers, thyroid antibody levels, or selected thyroid related parameters. However, larger meta analyses have generally not demonstrated consistent significant effects on TSH, free T4, or free T3 levels across studies.
The variability likely reflects differences in study design, probiotic strains, treatment duration, baseline thyroid status, and concurrent thyroid medication use.
Several probiotic strains have been explored in preliminary studies, including:
- Lactobacillus acidophilus
- Bifidobacterium longum
- Lactiplantibacillus plantarum 299v
Some studies suggest these organisms may:
- Support intestinal barrier function
- Influence microbial metabolic activity
- Reduce inflammatory signaling
- Affect thyroid antibody levels
At the same time, researchers are increasingly recognizing that probiotic effects are highly strain specific and context dependent. Emerging hypotheses suggest that under certain conditions, some bacterial proteins may share structural similarities with thyroid antigens, a phenomenon known as molecular mimicry. This remains an active area of investigation and highlights the complexity of host-microbiome interactions in autoimmune disease.
A 2025 randomized controlled trial found that combining probiotic supplementation with a health promoting dietary intervention improved quality of life and anti TPO parameters more effectively than dietary intervention alone in women with Hashimoto’s.
Prebiotic fibers also appear important because they help support the microbial environment necessary for SCFA production and growth of beneficial organisms.
At present, no probiotic strain has demonstrated sufficiently consistent evidence to support standardized clinical recommendations specifically for Hashimoto’s thyroiditis. This helps explain why someone may feel better after taking one probiotic but notice no benefit, or even worsening symptoms, with another.
An Emerging Role for the Oral Microbiome
An interesting newer area of research involves the oral microbiome.
Emerging evidence suggests oral bacteria may influence systemic immune signaling and potentially interact with both gut and thyroid immune pathways. Certain periodontal pathogens have been associated with heightened inflammatory activity in autoimmune thyroid disease.
While this research is still preliminary, it raises an important possibility: oral health may play a more meaningful role in autoimmune regulation than previously recognized. This does not mean gum disease causes Hashimoto’s, but it does reinforce that oral health is an important part of overall immune health.
Limitations of the Current Research
Despite growing interest in the gut-thyroid axis, important limitations remain.
Most microbiome studies in Hashimoto’s are observational and involve relatively small populations. Sequencing methods differ significantly between studies, making direct comparison difficult. Human intervention trials remain limited, and many probiotic studies vary substantially in strain selection, dosing, and duration.
Additionally, bacterial effects are often highly strain specific. Organisms traditionally considered beneficial may exert different immunologic effects depending on the host environment and broader microbial ecosystem.
In other words, the field is promising but still evolving.
What This Means for Patients
The emerging research on the gut-thyroid axis does not suggest that probiotics cure Hashimoto’s or that thyroid medication is unnecessary. But it does support a broader understanding of autoimmune thyroid disease, one that includes the gut as a meaningful participant in immune regulation and inflammatory signaling.
For many patients, especially those who continue to experience Hashimoto’s symptoms despite “normal” thyroid labs this research may help explain why symptom burden does not always correlate neatly with TSH alone.
It also reinforces the importance of addressing:
- Dietary quality and fiber diversity
- Gut health and digestion
- Inflammation
- Sleep and stress physiology
- Nutrient status
- Oral health
- Broader immune regulation
The future of Hashimoto’s care will likely be more integrative, more personalized, and more focused on immune and microbiome interactions than conventional thyroid care has historically been.
And we are only beginning to understand how meaningful that connection may be.
Frequently Asked Questions
Does Hashimoto’s start in the gut?
Current research suggests the gut may contribute to immune regulation in some people, but Hashimoto’s is a complex disease involving genetics, environmental triggers, hormones, nutrient status, infections, and immune function. The gut is likely one piece of a much larger puzzle.
Should everyone with Hashimoto’s take probiotics?
Not necessarily. Research is still evolving, and benefits appear to depend on the specific strain, the individual’s microbiome, and overall health.
Can healing the gut cure Hashimoto’s?
No evidence currently shows that improving gut health cures Hashimoto’s or eliminates the need for thyroid medication. However, supporting gut health may improve symptoms and overall immune regulation for some individuals.
Can improving gut health lower thyroid antibodies?
Possibly, but we don’t know for certain. Some small studies have found reductions in thyroid antibody levels with dietary changes or specific probiotic interventions, while others have not. At this point, evidence is encouraging but not strong enough to conclude that improving gut health consistently lowers thyroid antibodies.
What Can I Do Right Now?
While research is still evolving, current evidence supports focusing on habits that promote a healthy and diverse gut microbiome, including:
- Eating a wide variety of plant foods and fiber
- Including fermented foods if tolerated
- Managing chronic stress
- Prioritizing sleep
- Addressing constipation or digestive symptoms
- Maintaining good oral hygiene
- Working with a clinician to identify nutritional deficiencies or gastrointestinal conditions when appropriate
More in This Hashimoto’s Research Review Series
- Why You Still Feel Terrible with Normal Thyroid Labs: The Research on Euthyroid Hashimoto’s
- Hashimoto’s Winter Research Update 2022
Ready to Go Beyond the Research?
Understanding the science is the first step. Putting it into practice is where meaningful change happens.
If you’re looking for a supportive, evidence-based approach to managing Hashimoto’s, I’d love to have you join one of my Holistic Hashimoto’s Group Programs.
Learn more about upcoming groups here.
Selected References
Association Between Gut Microbiota and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis
Exploring the Role of Gut Microbiota in Autoimmune Thyroid Disorders: A Systematic Review and Meta-Analysis
The Composition of Gut Microbiota in Patients Bearing Hashimoto’s Thyroiditis With Euthyroidism and Hypothyroidism
Gut Microbiota and Autoimmune Thyroid Disease: A Bidirectional Mendelian Randomization Study and Mediation Analysis
Effects of Probiotics and Synbiotics Oral Supplementation on Thyroid Function in Adults
The Conspiring Role of Gut Microbiota as Primer of Autoimmune Thyroid Diseases: A Scoping Focus
This article is for educational purposes only and does not constitute medical advice.
